Neurodegenerative diseases pose a substantial socioeconomic burden on society.
Unfortunately, the aging world population and lack of effective cures foreshadow a negative …

Histone deacetylases (HADC) are the enzymes that remove acetyl group from lysine residue
of histones and non-histone proteins and regulate the process of transcription by binding to …

Alzheimer's disease is a chronic and progressive brain neurodegenerative disease affecting
over 30 million people globally. Currently, no effective treatment is available due to multiple …

The continued drug discovery failures in complex neurodegenerative diseases, including
Alzheimer's disease (AD), has raised questions about the classical paradigm “one‐drug …

Introduction: Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the
balance of acetylation and deacetylation of lysine residues of histones and non-histone …

Alzheimer's disease (AD) is a common neurodegenerative brain disorder that causes
cellular response alterations, such as impaired cholinergic mechanism, amyloid‐beta (Aβ) …

Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug
targets which have been studied intensively in the past few decades. Although several drugs …

Alzheimer's disease (AD) is one of the most common neurodegenerative disorders, which is
characterized by the primary risk factor, age. Several attempts have been made to treat AD …

Recently, despite the great success achieved by the so‐called “magic bullets” in the
treatment of different diseases through a marked and specific interaction with the target of …

Alzheimer's disease (AD) is a detrimental neurodegenerative disease that progressively
worsens with time. Clinical options are limited and only provide symptomatic relief to AD …